ABBV vs SBUX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Starbucks Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Starbucks Corporation · Consumer Cyclical
$96.60
-12.3% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
SBUX trades at a lower forward P/E
(42.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
SBUX |
| Current Price |
$197.69 |
$96.60 |
| Fair Value Estimate |
$210.22 |
$84.75 |
| Upside to Fair Value |
+6.3%
|
-12.3%
|
| Market Cap |
$349.7B |
$110.1B |
| Forward P/E |
83.3x
|
42.2x
|
| EV / EBITDA |
23.4x
|
22.5x
|
| Price / Sales |
5.7x
|
3.0x
|
| Price / FCF |
18.7x
|
45.1x
|
| Revenue Growth YoY |
+10.0%
|
+2.8%
|
| Gross Margin |
70.2%
|
24.2%
|
| Operating Margin |
26.7%
|
9.6%
|
| Return on Equity |
-361.6%
|
-22.9%
|
| Dividend Yield |
0% |
2.55% |
| FCF Yield |
5.35%
|
2.2%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Starbucks is the world's largest specialty coffee retailer with over 39,000 stores across 86 markets, generating $37.2B in annual revenue. Under CEO Brian Niccol, now 19 months into his tenure after joining from Chipotle in September 2024, the company is executing the Back to Starbucks operational turnaround focused on service speed, menu simplification, and store experience reinvention. At P/S 2…
Accumulation Zones
| Metric |
ABBV |
SBUX |
| Zone Low |
$157.66 |
$63.56 |
| Zone High |
$178.69 |
$72.04 |
| In Buy Zone? |
No
|
No
|